NYSE •
Healthcare •
Biotechnology •
Quote as of 06/09/2026 12:16
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization28.63 mln
Float90.22 mln
Earnings Date06/15/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-3.65
Highly reliable
Relative Strength
84
/ 100
Strongly outperforming
Debt / Equity
0.15
Very low leverage
ROE
-96.17
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
IGC Pharma Inc. is a pharmaceutical company focused on developing new treatments for Alzheimer's disease and other brain-related conditions, operating primarily in the United States and Colombia. Its most advanced drug candidate, IGC-AD1, is currently in Phase 2 clinical trials targeting agitation in Alzheimer's patients, while two earlier-stage compounds, TGR-63 and IGC-M3, are being explored as additional treatment options. The company also builds AI-powered tools to support healthcare providers in managing the disease. Founded in 2005 and based in Potomac, Maryland, IGC Pharma operates under a name it adopted in March 2023, having previously been known as India Globalization Capital Inc.
